PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25499383-8	2014	In the overall comparison, reduction of both SBP and DBP with eplerenone was greater than other antihypertensive agents (WMD for SBP -1.50 mm Hg, p < 0.0001; WMD for DBP -0.54 mm Hg, p < 0.00001); this was essentially driven by a greater anti-hypertensive action vs enalapril and losartan for SBP and vs losartan for DBP.	Eplerenone	62-72	selenium binding protein 1	Homo sapiens	129-132	
30985644-7	2019	Systolic/diastolic blood pressure (SBP/DBP) were reduced from 153.9 +- 12.6/84.6 +- 11.8 to 129.8 +- 14.2/73.7 +- 12.2 mm Hg by eplerenone therapy and from 152.2 +- 12.5/85.2 +- 10.9 to 133.8 +- 12.6/76.1 +- 8.6 mm Hg by trichlormethiazide therapy (all; P < .001).	Eplerenone	128-138	selenium binding protein 1	Homo sapiens	35-38	
25499383-7	2014	Compared to placebo, eplerenone significantly reduced either SBP [WMD -8.07, 95% CI -8.17 to -7.96 mm Hg, p < 0.00001] and DBP [WMD -4.08, -4.15 to -4.01 mm Hg, p < 0.00001].	Eplerenone	21-31	selenium binding protein 1	Homo sapiens	61-64	
25499383-4	2014	Randomized studies comparing eplerenone with placebo or other antihypertensive drugs for net reduction of systolic and diastolic blood pressures (SBP; DBP) from baseline and for incidence of adverse events were considered.	Eplerenone	29-39	selenium binding protein 1	Homo sapiens	146-149	
23314743-7	2013	RESULTS: Eplerenone significantly decreased more 24-h ambulatory SBP on day 66 than LCI699 on day 29 and the difference between the two treatment was -5.34 [95% confidence interval (CI) -10.30; -0.38)] mmHg (P = 0.027).	Eplerenone	9-19	selenium binding protein 1	Homo sapiens	65-68